Aimed Alliance Urges CT Governor to Consider PDAB Alternatives
On August 27, 2024, Aimed Alliance sent Connecticut Governor Ned Lamont a letter urging the Governor to consider alternatives to…
Browsing: Drug Pricing: Policy Activity
Aimed Alliance Publishes New Resource on PDAB & IRA Implications for Rare Disorders
On August 20, 2024, Aimed Alliance released a new fact sheet on, “IRA, PDABs, & Orphan Drugs: How Price Setting…
Colorado PDAB Calls for Strengthening Consumer Input
Colorado’s Prescription Drug Affordability Board (PDAB) has issued recommendations to the state legislature aimed at enhancing consumer involvement, adjusting eligibility…
Maryland PDAB Meets to Discuss Drug Cost Review Process
On July 22, 2024, the Maryland Prescription Drug Affordability Board (PDAB) met to discuss the upcoming timeline for the next…
Oregon PDAB Meeting Highlights Diverse Perspectives on UPLs
On July 24, 2024, the Oregon Prescription Drug Affordability Board (PDAB) held seven panels related to upper payment limits (UPLs),…
New White Paper Explains Why AFP Savings May Fall Short of Expectations
A new White Paper titled “Pharmacy Benefit Alternative Funding Programs: Key Considerations for Self-Funded Plan Sponsors” details how the saving…
FTC Report Unveils PBM Impact on Drug Costs and Accessibility
On July 9, 2024, the Federal Trade Commission (FTC) released an interim report highlighting the significant impact of pharmacy benefit…
Aimed Alliance Provides Comment on Medicare Drug Price Negotiation Program Guidance
On July 2, 2024, Aimed Alliance submitted a comment to the Centers for Medicare & Medicaid Services (CMS) regarding the…
Oregon PDAB Postpones Drug Reviews Until 2025
On June 26, 2024, the Oregon Prescription Drug Affordability Board (PDAB) voted to pause all ongoing drug reviews for the…
Colorado’s PDAB Declares Third Drug Unaffordable
On June 14, the Colorado Prescription Drug Affordability Board (PDAB) voted that a prescription drug used to treat various forms…